(Q36583822)

15 August 2017

1 reference

title

Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease (English)

1 reference

15 August 2017

1 reference

E A Mayer

1

1 reference

15 August 2017

K Tillisch

series ordinal

2

1 reference

15 August 2017

S Bradesi

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Alimentary Pharmacology & Therapeutics

15 August 2017

published in

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

919-933

1 reference

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Treating irritable bowel syndrome: overview, perspective and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Treatments targeting putative mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The neurobiology of stress and gastrointestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The usual medical care for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Evaluation of drug treatment in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Use of psychopharmacological agents for functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

How do you feel? Interoception: the sense of the physiological condition of the body

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Basic and clinical aspects of visceral sensation: transmission in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Evolving pathophysiologic models of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Controller-regulator model of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Functional mapping of the insular cortex: clinical implication in temporal lobe epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Spinal and supraspinal contributions to central sensitization in peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Perceptual wind-up in the human oesophagus is enhanced by central sensitisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Chronic pain and medullary descending facilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Buspirone inhibits corticotropin-releasing factor and stress-induced cecal motor response in rats by acung through 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Management of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Evolution of visceral sensitivity in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Role of serotonin in the pathophysiology of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Plasticity in serotonin control mechanisms in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Expression of 5-HT3 receptors by extrinsic duodenal afferents contribute to intestinal inhibition of gastric emptying

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Descending serotonergic facilitation mediated through rat spinal 5HT3 receptors is unaltered following carrageenan inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Bad news from the brain: descending 5-HT pathways that control spinal pain processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Potential use of drugs modulating 5HT activity in the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Review article: the role of inflammation in the pathogenesis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Alosetron and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Lotronex and the FDA: a fatal erosion of integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

New drugs in the management of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effects of octreotide on responses to colorectal distension in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

NK1 (substance P) receptor antagonists--why are they not analgesic in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Do substance P and the NK1 receptor have a role in depression and anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Peristalsis regulation by tachykinin NK1 receptors in the rabbit isolated distal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Neurokinin(1) receptor antagonists as potential antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Expression of the bile salt export pump is maintained after chronic cholestasis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

MEN 11420, a potent and selective tachykinin NK2 receptor antagonist in the guinea-pig and human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Peripheral CRF activates myenteric neurons in the proximal colon through CRF(1) receptor in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Analgesia produced by clonidine in mice and rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Alpha-2 adrenergic transmission and human baroreflex regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

CCK enhances response to gastric distension by acting on capsaicin-insensitive vagal afferents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Involvement of endogenous CCK and CCK1 receptors in colonic motor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Cholecystokinin pathways modulate sensations induced by gastric distension in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Increased food intake and CCK receptor antagonists: beyond abdominal vagal afferents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

NMDA and quisqualate modulation of visceral nociception in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

NMDA receptor antagonists attenuate noxious and nonnoxious colorectal distention-induced Fos expression in the spinal cord and the visceromotor reflex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Oral S(+)-ketamine does not change visceral perception in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

Clinical determinants of health-related quality of life in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03078.X

10.1111/J.1365-2036.2006.03078.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference